anti-IgE antibody

anti-IgE antibody

Allergy medicine An antibody directed against IgE. See Allergy.
Mentioned in ?
References in periodicals archive ?
Switzerland-based Novartis has started phase three trials for its monoclonal anti-IgE antibody (ligelizumab) in chronic spontaneous urticarial (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines, it was reported yesterday.
As the first monoclonal anti-IgE antibody, omalizumab has been confirmed to improve the asthma symptom score, reduce the acute attack of asthma, lower the dosage of oral or inhaled glucocorticoid, and ameliorate life quality of asthma patients.
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol.
Downregulation of Fc(epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-45.
ORLANDO--Omalizumab, a monoclonal anti-IgE antibody, may be a good option for patients with treatment-refractory bullous pemphigoid (BP).
Pellegrino, "The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology," Panminerva Medica, vol.
Studies using anti-IgE antibody in food allergy management are limited, but show promising results.
Currently available treatment using omalizumab (an anti-IgE antibody sold under the trade name Xolair) can block new interactions between IgE and FcR, but it is not designed to pry the molecules apart once they've formed a bond on the surface of a mast cell.
These results suggest that, after incubation with CAF, the anti-IgE antibody used in ELISA was unable to detect the IgE.
(18) Omalizumab is a humanised monocolonal anti-IgE antibody that works by binding free IgE and thus preventing the interaction between free IgE and both the high and low affinity IgE receptors on inflammatory cells, such as basophils and mast cells.
It has been established that anti-IgE antibody induces passive cutaneous anaphylaxis (PCA) as a typical in vivo model for immediate hypersensitivity in anaphylactic reactions.
2003;167:1232-8), and the humanized monoclonal anti-IgE antibody omalizumab (Int.